Furthermore, an ad hoc trial comparing the combined TOFA doses with a TNF inhibitor in a cardiovascular risk-enriched population, highlighted the possibility that the risk of major adverse cardiovascular events (MACE) and cancers was higher with TOFA, as non-inferiority criteria was not achieved (67). This evidence concerns the gene TNF and cancer.